プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Dr. Divyaanka I.に依頼

Singapore

Freelance scientific writer with research experience in oncology, metabolic diseases and bacteriology

プロフィール概要

I am a published researcher with 10 + years of experience in the field of oncology, metabolic & infectious diseases. I have knowledge of clinical trials and lead molecules in oncology and have developed an anti-cancer molecule for which I have a patent. My passion for science is tied to communication and I can effectively translate scientific data and concepts to the written word. My writing experience includes research articles, book chapter, reviews and research grants. I understand the requirements of each of these formats and can deliver content to high standards of scientific accuracy and readability. I have also successfully extended my editorial and written expertise beyond academics to editing business case studies and generating sponsorship proposals to government bodies and private companies. I look forward to exciting work in my area of expertise and delivering high quality within acceptable timelines.

専門分野

• ★ Oncology
• ★ Infectious Disease
• ★ Metabolism & Metabolic Disease
• ☆ Biochemistry
• ☆ Oxidative Stress & Mitochondrial Function
• ☆ Molecular Biology
• ☆ Cell Signaling Pathways
• ☆ Inflammation

サービス

• Writing

Writing Clinical Trial Documentation, Technical Writing

職務経験

Postdoctoral Research Fellow

Duke-NUS Medical School

4月 2019 - 9月 2019

CSIR Nehru Postdoctoral Research Fellow

CISR- Institute of Genomics and Integrative Biology

5月 2016 - 6月 2018

Research Associate

Indian institute of science

7月 2014 - 11月 2014

学歴

PhD

Indian Institute of Science

8月 2007 - 1月 2014

MSC Genetics

Osmania University

5月 2005 - 5月 2007

BSC Microbiology, Biochemistry, Chemistry

St Francis College for Women, Osmania University

4月 2002 - 4月 2005

認定資格

• 認定資格の詳細は未入力です。

出版物

JOURNAL ARTICLE

(2017). Mitochondrial Function in Allergic Disease . Current allergy and asthma reports.

(2017). Novel BCL2 inhibitor, Disarib induces apoptosis by disruption of BCL2-BAK interaction . Biochemical pharmacology.

(2016). A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis . Biochemical pharmacology.

(2016). Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain . The FEBS journal.

PATENT

(2017). Novel Inhibitors of Antiapoptotic BCL-2 protein .

BOOK CHAPTER

Targeted Cancer Therapy: The Role of BCL2 Inhibitors . Biotechnology Volume-7 (Drug Discovery).